A research on mood disorder pathophysiology has hypothesized abnormalities in glutamatergic neurotransmission, by suggesting further investigation on glutamatergic N-methyl-Daspartate (NMDA) receptor modulators in treating Major Depressive Disorder (MDD). Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an intranasal formulation for treatment-resistant depression (TRD) and for rapid reduction of depressive symptomatology, including suicidal ideation in MDD patients at imminent risk for suicide.
An Update on Glutamatergic System in Suicidal Depression and on the role of Esketamine / De Berardis, Domenico; Tomasetti, Carmine; Pompili, Maurizio; Serafini, Gianluca; Vellante, Federica; Fornaro, Michele; Valchera, Alessandro; Perna, Giampaolo; Volpe, Umberto; Martinotti, Giovanni; Fraticelli, Silvia; Di Giannantonio, Massimo; Kim, Yong-Ku; Orsolini, Laura. - In: CURRENT TOPICS IN MEDICINAL CHEMISTRY. - ISSN 1568-0266. - STAMPA. - 20:(2020). [10.2174/1568026620666200131100316]
An Update on Glutamatergic System in Suicidal Depression and on the role of Esketamine
Serafini, Gianluca;Volpe, Umberto;Orsolini, Laura
2020-01-01
Abstract
A research on mood disorder pathophysiology has hypothesized abnormalities in glutamatergic neurotransmission, by suggesting further investigation on glutamatergic N-methyl-Daspartate (NMDA) receptor modulators in treating Major Depressive Disorder (MDD). Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an intranasal formulation for treatment-resistant depression (TRD) and for rapid reduction of depressive symptomatology, including suicidal ideation in MDD patients at imminent risk for suicide.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
